Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
Results support potential for dostarlimab to eliminate the need for chemotherapy, radiation and surgery in some patients
Read the full articleYou might also wanna read
GSK Achieves Promising Results in Rectal Cancer Trial with Jemperli
Related Stocks: GSK
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
Conditions : Local Advanced Rectal Cancer; PD-1 Inhibitor; PCSK9 Inhibitor; RCT; Radiotherapy; Capecitabine; Oxaliplatin Interventions : Rad
GSK’s Jemperli meets main goal in mid-stage rectal cancer trial
July 13 (Reuters) - GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rat
GSK to file Jemperli for rectal cancer after phase 3 readout
GSK to file Jemperli for rectal cancer after phase 3 readout Phil.Taylor Mon, 13/07/2026 - 11:42
Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation
Conditions : Rectal Cancer Patients Interventions : Drug: Long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib Sp
Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer
Conditions : Local Advanced Rectal Cancer; Radiotherapy; Immunotherapy Interventions : Radiation: Short-Course Radiotherapy; Drug: Consolida
Comments
Sign in to join the conversation.
No comments yet. Be the first.